Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A

As of June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A carries a market capitalization of 2.85B, placing it among publicly traded companies globally. Its enterprise value stands at 3.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A's next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A has 76.92M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.41, and the price-to-book ratio stands at 0.89.

As of June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A trades at an EV/EBITDA multiple of 66.60 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.28B versus a market cap of 2.85B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A maintains a current ratio of 4.06, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 23.59, indicating elevated leverage, while an interest coverage ratio of 3.21 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A posted a negative return on equity (ROE) of -1.60, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.16, reflecting losses generated across the asset base. The company generates approximately 2.69M in revenue per employee across its workforce of 347.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.05 indicates how many times Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A recorded 18.61M in income tax expense. The company reported a pretax loss of -33.10M and -51.70M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A's stock has gained approximately 23.76% over the past 52 weeks. The 50-day moving average sits at 34.72, while the 200-day moving average is 32.29.

Over the twelve months ended June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A generated 934.29M in revenue and converted that into -51.70M in net income, yielding earnings per share of -0.85. EBITDA reached 49.24M, while operating income came in at -136.52M.

As of June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A holds 329.96M in cash and equivalents against 755.63M in total debt, resulting in a net debt position of 421.97M. Total book value stands at 3.20B, with working capital of 870.24M providing operational flexibility.

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A produced 291.54M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -43.09M in capital expenditures, free cash flow totaled 248.45M - equivalent to 4.09 per share.

Over the twelve months ended June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A posted a gross margin of 17.95, reflecting its pricing power and cost economics. The operating margin of -14.61 and net profit margin of -5.53 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 11.03, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.09, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A shareholders.

As of June 30, 2026, Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A has an Altman Z-Score of 2.33, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.